Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor.

Trial Profile

Phase II Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-Positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2016

At a glance

  • Drugs Dasatinib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jul 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Planned End Date changed from 1 May 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top